• Vaccine Name: ALVAC-FL- env/gag
• Target Pathogen: Feline leukemia virus
• Target Disease: Feline leukemia virus infection
• Vaccine Ontology ID: VO_0004740
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• env from FeLV-A/Glasgow gene engineering:
  • Type: Recombinant vector construction
  • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
  • Detailed Gene Information: Click Here.
• gag gene engineering:
  • Type: Recombinant protein preparation
  • Description: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes were assessed for their protective efficacy in cats. Both recombinant viruses contained the entire gag gene. ALVAC-FL also expressed the entire envelope glycoprotein, while ALVAC-FL(dl IS) expressed an env-specific gene product deleted of the putative immunosuppressive region (Tartaglia et al., 1993).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001128
• Preparation: Two ALVAC (canarypox virus)-based recombinant viruses expressing the feline leukemia virus (FeLV) subgroup A env and gag genes (Tartaglia et al., 1993).
• Immunization Route: Intramuscular injection (i.m.)

Cat Response

• Vaccination Protocol: Cats were vaccinated with ALVAC-FL(dI IS) or ALVAC-FL, consisting of two subcutaneous inoculations of 10^8 PFU at 5 and 2 weeks prior to challenge (Tartaglia et al., 1993).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: All cats were challenged by oronasal administration of 2 x 10^6 FFU of FeLV-A/Glasgow-1 isolate to simulate natural transmission (Tartaglia et al., 1993).
• Efficacy: Although only 50% of the cats vaccinated with ALVAC-FL(dl IS) were protected against persistent viremia after oronasal exposure to a homologous FeLV isolate, all cats administered ALVAC-FL resisted the challenge exposure. Significantly, protection was afforded in the absence of detectable FeLV-neutralizing antibodies (Tartaglia et al., 1993).